229 related articles for article (PubMed ID: 15886755)
1. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
2. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
[No Abstract] [Full Text] [Related]
3. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
4. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
[TBL] [Abstract][Full Text] [Related]
5. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.
Watanabe N; Kanegane H; Kinuya S; Shuke N; Yokoyama K; Kato H; Tomizawa G; Shimizu M; Funada H; Seto H
J Nucl Med; 2004 Apr; 45(4):608-11. PubMed ID: 15073256
[TBL] [Abstract][Full Text] [Related]
6. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
7. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
8. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
9. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer.
Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S
Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057
[TBL] [Abstract][Full Text] [Related]
10. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
[TBL] [Abstract][Full Text] [Related]
11. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
13. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
14. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
16. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
17. The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy.
Song EY; Rizvi SM; Qu CF; Raja C; Yuen J; Li Y; Morgenstern A; Apostolidis C; Allen BJ
Phys Med Biol; 2008 Jan; 53(2):319-28. PubMed ID: 18184988
[TBL] [Abstract][Full Text] [Related]
18. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
Lassmann M; Hänscheid H; Reiners C; Thomas SR
J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
[No Abstract] [Full Text] [Related]
19. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes.
Livingston GK; Foster AE; Elson HR
J Toxicol Environ Health; 1993; 40(2-3):367-75. PubMed ID: 8230307
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer.
Vrndic O; Milosevic-Djordjevic O; Djurdjevic P; Jovanovic D; Mijatovic L; Jeftic I; Simonovic SZ
Neoplasma; 2013; 60(5):568-75. PubMed ID: 23790177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
